Antylia Scientific Acquired by Private Equity Firms (~12.4x EBITDA)
- Will Hamilton
- May 29, 2025
- 2 min read
On May 28, 2025, global alternative asset manager Brookfield Asset Management, alongside Caisse de dépôt et placement du Québec (CDPQ), announced the acquisition of GTCR’s Antylia Scientific, a U.S.-based integrated provider of scientific research tools, laboratory services and specialty instruments serving biopharma, diagnostics and academic markets. Antylia’s platform combines branded products, custom solutions, and technical services that address complex laboratory needs across life sciences and advanced research segments. The investment aligns with Brookfield and CDPQ’s broader theme of backing high-quality, mission-critical infrastructure and services in healthcare and life sciences, particularly where specialized expertise and recurring revenue models underpin durable cash flows.
The transaction marks a strategic investment by Brookfield and CDPQ into the science tools and services sector, reflecting confidence in the resilient demand for advanced laboratory capabilities and consolidative growth opportunities. Financial terms were not publicly disclosed. The investment aligns with Brookfield and CDPQ’s broader theme of backing high-quality, mission-critical infrastructure and services in healthcare and life sciences, particularly where specialized expertise and recurring revenue models underpin durable cash flows. For Antylia, the partnership is expected to accelerate product innovation, geographic expansion, and value-add acquisitions while enhancing operational capabilities through Brookfield’s capital base and CDPQ’s industrial expertise. In the context of 2025 healthcare M&A dynamics, the deal underscores continued investor interest in scalable scientific tools and services platforms that support biopharmaceutical R&D and complex laboratory workflows, reinforcing the sector’s resilience against economic cyclicality.
Life Sciences Equipment EBITDA Multiples
The press release discloses a $1.34 billion purchase price. According to bond market research published by S&P, Antylia generated revenue of $395 million in 2024, and EBITDA margins are expected to be ~27.4% ($108m), implying multiples of 3.4x revenue and 12.4x EBITDA. The research also discloses anticipated pro forma leverage of 6.8x post-transaction debt of $740m, further supporting the $108m EBITDA figure.
Diagnostics and Life Sciences M&A Deal Volume
The number of announced diagnostics and life science deals appears to be on the upswing after a somewhat weak 2024. Deal volume is in the low 30s per quarter on 2024, which is just slightly below 2021 averages. Announced volumes dipped to an average of 29 per quarter in 2024. Diagnostic tools and life sciences have been the best performing subsectors, highlighting the broader positive trends in healthcare technology, while laboratories, equipment, and collection network M&A volumes have been weaker.
Other Diagnostics / Life Sciences Deals
Read Scope Research's take on other diagnostics and life sciences M&A transactions:
About Scope Research
The Scope Research Healthcare M&A Valuation Database currently has financial details related to 232 diagnostics and life sciences deals, segmented by type, including 102 deals with disclosed EBITDA multiples. The data can be purchased individually, while our affordable annual subscriptions provide access to all of our healthcare M&A databases and segments, updated continuously.
Don't hesitate to reach out to Will Hamilton at will@scoperesearch.co with questions about your specific situation.
